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1INTRODUCTION
Haemophilia A is a common, X-linked, inherited congenital bleeding
disorder. It is caused by dysfunctional or deficient production of coagulation
Factor VIII (FVIII). Factor 8 gene is located in the long arm of X
chromosomes. It is one of the largest  gene with the molecular weight of 260
kDa . Since it is a X - linked  recessive  disorder ,it occurs in males and the
females are carriers.2 As early as in the 2nd century, hemophilia was recognised
and the cardinal features of hemophilia were described.3 Since 1937,it was
found that  the plasma component Anti hemophilic factor, named as  Factor
VIII was deficient in hemophilia  patients .Factor VIII plays a critical role in
the propagation phase of coagulation. 4
The incidence of haemophilia A is 1 in 5000 male live births. Estimated
of Haemophilia A is one in 10,000 births approximately.5 World Federation of
Hemophilia Survey indicate the number of hemophilia in the world wide is
approximately 4,00,000 .5 Hemophilia  A  prevalence is “the total number of
reported or identified cases of Haemophilia A in the population  at a given time
divided by the total number of males in that population”.6  In India ,the number
of expected Patients with hemophilia would be approximately
120000.According to World  Federation of Hemophilia Global survey 2010
only 13993 patients were registered. This indicates the gross under diagnosis,
early deaths and lack of awareness to access treatment facilities.80 The
prevalence of Haemophilia A for high income countries was 12.8 per 100 000
2males and 6.6 per 100 000 males in the rest of the world.5 Haemophilia A is
more common than Haemophilia B ,representing 80-85% of the total
haemophilia population.7
Clinical manifestations of Haemophilia A are easy bruising,
spontaneous bleeding into the joints , muscles and soft tissues, excessive
bleeding after trauma.5  Classification of hemophilia is based on plasma
procoagulant levels with persons <1% factor defined as severe,1-5% as
moderate,>5% and less than 30% is mild.9 In mild  haemophilia ,the patient
bleed excessively only after trauma or surgery. Patients with Severe
haemophilia A have spontaneous bleeding or excessive bleeding after minor
trauma,  particularly  into joint muscles.9
Treatment of Haemophilia A patients relies on administration of
exogenous Factor VIII either in the form of Fresh Frozen plasma/
cryoprecipitate ,plasma derived  Factor VIII or recombinant Factor VIII.9 The
current standard of care for Haemophilia A patients is either on demand  or
prophylactic.10  Plasma derived Factor VIII concentrates used for
supplementation therapy in the 1980s were frequently contaminated with
human deficiency virus. Hepatitis B and C viruses causing mortality in a large
hemophilic population .11 The problems related with transfusion transmitted
infections  can be prevented by the use of recombinant Factor VIII.
3             Development of antibodies against the exogenous Factor VIII is the
major potential complication of the treatment of Haemophilia A. This
antibodies are known as inhibitors .12 These Factor VIII inhibitors   are  IgG
immunoglobulins.
            Inhibitors are classified according to their levels in plasma as high titre,
those with ?5 Bethesda units/ml and low titre inhibitors <5 Bethesda units/ml.
Some   patients develop transient inhibitors ,these are low titre inhibitors that
never exceed a titre of 5 BU/ml and disappear spontaneously with time.8 One
Bethesda unit is defined as the inhibitory titre needed to inactivate 50 percent
of the Factor VIII present in normal plasma within 2 hour incubation period at
37°C.13
             Over the years, numerous risk factors both treatment related and patient
related have been identified. The development of inhibitors related to the
patient characteristics including severity of the disease, ethnicity, and mutation
involved in F8 gene, family history of inhibitors and the treatment related risk
factors like intensity of Factor VIII exposure, early exposure to Factor VIII and
product type.  According to the severity of disease, the persons with severe
haemophilia A are at greatest risk for inhibitor development .14  Risk of
inhibitor formation has varied between 20-30% in patients with severe
haemophilia  A and 3-13% in those with mild or moderate haemophilia A.15
4         Presence of inhibitor is a challenging problem in the treatment of
Haemophilia A to control bleeding manifestation, maintain the haemostasis and
overall quality of life.16 Inhibitor assays are performed in haemophilia A
patients as a screening procedure when the presence of inhibitor is suspected in
the case of abnormal bleeding  in spite of taking Factor VIII or poor response
to Factor VIII replacement therapy. Among the haemophilia  A patients facing
the challenges, the development of inhibitors is the most feared one.
With this background our study aims to describe the prevalence of
inhibitors   and the association between the risk factor and inhibitor
development.
5AIMS & OBJECTIVES
Aim :
Aim of our study is to find out the prevalence of Factor VIII inhibitors
in haemophilia  A patients who received plasma derived Factor VIII therapy.
OBJECTIVES  :
? To estimate the Factor VIII levels and classify the haemophilia A
? To  Identify the risk factors for inhibitor development
6REVIEW OF LITERATURE
Haemophilia A is the most common severe inherited bleeding disorder.4
The hereditary and sex linked nature of the disease was recognized since
ancient times. As early as in the 2nd century the haemophilia was recognized in
the Jewish writings. Rabbinic references showed the characteristic feature of
the disease was the fatal bleeding after minor injury in brothers or in maternally
related boy cousins.3 In the 10th  century  , khalaf ibn abbas described the males
who bled to death after minor injury.3 The Arabic physician Albucasis who
lived in the 12th century described males in a family died after a trivial
injury.3,17 In the 18th century   Dr John Conrad otto a physician from
philadelphia  described the cardinal features of haemophilia ,the symptoms
were shown only by males, the unaffected  females transmit  the disease to a
proportion of their sons.17,3 In 1828 Hopff   who was the student at the
university of zurich who is the first one use the term “HAEMOPHILIA”. In
1890, the involvement of joint is the characteristic symptom of haemophilia
was described by konig. Haemophilia has been called the ROYAL DISEASE.
Queen Victoria of ENGLAND (1837-1907) was a carrier of the haemophilia
gene and subsequently passed the disease on to several royal families.3The
bleeding   tendency of haemophilia was due to fragility of blood vessels..In
1930 ,the deficiency of platelets were thought to be the main cause of
bleeding.25Since 1937 Peter J studied the deficiency of plasma component had
some association with Haemophilia, then  Patek and Taylor described about the
“Anti Haemophilic factor”  was  derived from  the plasma of normal individual
which one corrects  the clotting defect of haemophilia. After that according to
7the recent nomenclature that anti haemophilic factor was known as Factor
VIII.18
In the 19th century Quick described  the laboratory definition included
the concepts of long blood clotting time, normal  prothrombin time, normal
platelets count but an obvious prolongation of the plasma clotting time after
spinning down the platelets. After laboratory work  up , they found ,the
reduction of Factor VIII is the central feature of haemophilia.3 Haemophilia A
is the inherited  deficiency of blood coagulation factor leads to lifelong
bleeding disorder ,the factors most commonly found  deficient are factor VIII
and factor IX these genes are located in the X chromosomes.1 Haemophilia A is
an X-linked congenital bleeding disorder resulting from a deficiency of Factor
VIII.20 Since these disorders are X- linked they usually occurs in males.2 The
world wide incidence of haemophilia A is  approximately  1 case per 5000
male individuals.9 30% of cases a spontaneous mutation and there is no family
history of haemophilia.2,4 Female carriers are expected to have a plasma
concentration of factor VIII corresponding to half the concentration found in
healthy individuals, which is generally sufficient for normal haemostasis..4 50%
chance of carrier mother transmit the defective X -linked gene to the male or
female child. All female offspring are obligatory carriers born to carrier
father.21 Even though  the severe cases of hemophilia is rare in female, genetic
mechanism can result in clinical manifestation of  haemophilia A in females
.The  genetic mechanisms involved 4 are Inheritance of homozygous F8
mutation, Skewed inactivation of the X chromosome , X/O   karyotype: Turner
syndrome  and  X/   autosome   translocation.10% higher incidence seen in the
consequence of  consanguineous  marriages.7
8FIGURE.I. PEDIGREE CHART
The Inheritance of hemophilia A and Hemophilia B. The pedigree is hypothetical
Squares indicate male; circles indicate female; fully shaded squares or circles indicate
affected members: half – shaded circles indicate carriers.
FIGURE .2.THE STRUCTURE OF FACTOR VIII PROTEIN
9STRUCTURE OF FACTOR VIII :
 FVIII gene is located in the long arm of X chromosome. It is one of the
largest genes known with the molecular weight of 260 kDa.4 It spans over 180
kb. Analysis of the primary structure showed the presence of discrete domain
structureA1-a1-A2-a2-B-a3-A3-C1-C2.The A domain display approximately
30% homology to each other, C domains are  structurally related to factor V,
the B domain is unique ,no significant homology with any other protein. The
Factor VIII gene comprises 26 exons which encode polypeptide chain of 2351
amino acids. This includes signal peptide of 19 and a mature protein 2332
amino acids. Rough endoplasmic reticulum and Golgi apparatus of
hepatocytes, are the primary source of FVIII in liver but not in sinusoidal cells
and endothelial cells.18
SECRETION AND CIRCULATION OF FACTOR VIII :
 The FVIII is secreted into the circulation, after synthesis in the
hepatocytes, in the circulation it forms non covalent bond with vWF .The
plasma concentration of FVIII and vWF is 100 to 200 ng /ml and 10µg/ml
respectively. vWF binds to the A3 and  C2 regions of FVIII through sequence
in the D´/D3 region of the mature vWF  monomer. In the plasma vWF protects
FVIII from proteolysis by activated protein C. Without this interaction the
plasma half life of FVIII is reduced and the plasma levels of FVIII are low.4
10
FIGURE.3.COAGULATION CASCADE CELL BASED MODEL
FIGURE.4.INTRINSIC TENASE COMPLEX FORMATION
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FVIII plays a critical role in the propagation phase of coagulation
.Thrombin is the physiological activator of FVIII, which proteolytically cleaves
the  FVIII at three sites, Arg 372 at the NH2 terminus of the A2 domain,  Arg
740 at the NH2 terminus of B domain and Arg 1689   at the NH2 terminus of
the A3 domain. These cleavage results in the release of FVIII from vWF and
the formation of non covalently associated   activated FVIIIa. Activated FVIII
forms essential cofactor activity in the intrinsic tenase  complex , where FIXa is
the serine protease  and FX is the substrate. FVIIIa enhances the catalytic
reaction about 200,000 fold. Severe deficiency   profoundly reduces the rate of
generation of   FXa
FIGURE.5. FACTOR VIII PROTEIN ACTIVATION AND INACTIVATION
Two   processes   were involved in the inactivation of   FVIIIa.
         1. Spontaneous dissociation of the A2 domain
         2. Activated protein C mediated proteolysis at Arg 562 in the
FVIIIa heavy chain.
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MOLECULAR   DEFECTS   IN HAEMOPHILIA A:
Impaired transcription, RNA processing or translation of FVIII gene are
due to gross deletion or rearrangements of gene ,it may result in reduced
synthesis of factor VIII or the release of dysfunctional FVIII .Single missense
mutation cause defective secretion.22  A defect located outside the FVIII gene
also the cause of reduced levels of FVIII gene. 40-50% of the haemophilia A
has an association with intron 22 inversion .40% of the cases are caused by an
inversion involving a gene within intron 22 of the FVIII gene. Inversion in
intron 1 has also been detected recently. Severe deficiencies associated with
missense mutation in which impaired folding and or altered conformation of
the mutant FVIII lead to both intra and extracellular instability which in turn
causes severe factor deficiency in plasma. 19,23,22,24
CLASSIFICATION OF HAEMOPHILIA A:
Classification of the severity of haemophilia has been based on either
clinical bleeding symptoms or plasma procoagulant levels ,the later is widely
used.8 The amount of residual FVIII present determines the clinical variability
of the disease.22Haemophilia A classified  as mild (6%to 30%FVIII level)
,moderate (1 to 5%)and severe(<1%).16  Haemophilia  was  classified  based on
clinical symptoms, because severe haemophiliacs may exhibit no  spontaneous
bleeding and  appears to be clinically normal, conversely midland moderate
haemophilia  patient may have frequent spontaneous bleeds and appear to be
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clinically severe.8  Mild haemophiliacs bleed excessively only after trauma or
surgery.  Severe haemophilia   have an average of 20 to 30 episodes of
spontaneous or excessive bleeding after minor trauma.16.
CLINICAL  FEATURES OF HAEMOPHILIA A:
Dysfunctional factor VIII disrupts the normal intrinsic coagulation
cascade. based   on factor VIII  activity .26 The bleeding tendency is determined
by the baseline level of the deficient or defective clotting factor. Spontaneous
bleeding is frequent in severe haemophiliacs.4 In mild hemophilia ,spontaneous
bleeding is infrequent but prolonged and excessive bleeding occur after trauma,
invasive surgical or dental procedures.4,26 Haemarthrosis is a classical clinical
sign of severe hemophilia.4 Common sites involved are ankle, knee, elbow. In
addition to joint bleeding prolonged soft tissue and mucocutaneous bleed also
common in hemophilia A. Epistaxis is not a common feature of haemophilia
but it can occur.4 Hematuria is common in haemophiliacs. Gastro intestinal
bleeding occur in haemophilia A adult those who are using NSAIDs for
haemophiliac arthropathy. Intra cranial haemorrhage is   most common in both
neonates and children with hemophilia .The incidence in newborn with severe
hemophilia is 3,5% to 4%.incidence is highest in neonates associated with
traumatic vaginal delivery.4 Intra cranial hemorrhage in patients younger than
18 years and can be fatal.27
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1950s and 1960s, haemophiliacs could be treated only with whole blood
or fresh plasma, in severe haemophiliac patients, quantity of FVIII in fresh
plasma is not enough to stop hemorrhage after surgery or trauma or in vital
organs. In 1964 Judith pool discovered that cryoprecipitate from  plasma
contained large amounts of FVIII.17  The lyophilised plasma concentrates of
coagulation  factors  were  available  in  1970s and the widespread adoption of
home replacement therapy led to the control of haemorrhage. For producing
plasma derived Factor VIII concentrate the large size of donor pools were
included, this was heightened the risk of viral contamination.27 In 1980s the
people who received the plasma products were infected with HIV and HCV.3
.As a consequences of this, the need for safe treatment became crucial for the
haemophilia community.27 The viral inactivation techniques been developed
and implemented for the production of plasma derived FVIII concentrates, the
new methods been adopted in for transfusion transmitted infection.19 In 1984
the rapid progression in DNA technology, allowed the industrial production of
recombinant FVIII.17 In  1987 March, the recombinant FVIII was infused in a
haemophilia patient.28  rFVIII  is derived through heterologous transfection
rFVIII  DNA plasmids into a non human mammalian cell line, either Chinese
hamster ovary or baby hamster kidney cells. The expressed proteins are then
secreted into a culture medium containing human or bovine protein for
stabilisation. The recombinant proteins are then purified via various
chromatographic techniques.28 The improvement of protein purification
techniques the addition of viral inactivation steps recombinant helped to reduce
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the TTI.17 Advancement in developing the recombinant FVIII ,the majority of
patients in developed countries treated with recombinant products.29 Several
recombinant Factor VIII products are available ,the majority of them
containing full length Factor VIII molecules  stabilized either by human serum
albumin or sucrose solution.30 Another type is B  domain  depleted  rFVIII
approximately 38% of the primary cDNA could be removed  without  loss of
procoagulant activity was demonstrated. No addition of plasma derived
albumin was needed for stabilization of the final product. when compared to
full length rFVIII  BDD-rFVIII provided safe, well tolerated and effective
treatment of haemophilia A.28 However the TTI can be avoided by
recombinant, the major complication of infusion of exogenous FVIII is the
development of inhibitory  allo  antibodies against exogenous FVIII.
FACTOR VIII  INHIBITORS :
INTRODUCTION :
Apart from TTI  complication ,the inhibitor development is the most
significant complication20, it is a complex interaction between patient’s
immune system and genetic and environmental risk factors.31 Inhibitors reduce
the efficacy of haemostatic treatment and clearly cause additional morbidity.32
”Prevalence indicates only proportion of patients with an inhibitor at an
particular period of time”.33
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IMMUNOBIOLOGY OF FVIII INHIBITORS:
Synthesis of inhibitors depends on the activation of CD4+(helper) T cells
specific for FVIII .34
? Administered FVIII  molecule is endocytosed by a antigen presenting
cell(APC)
? Intra cellular proteolytic degradation ->generation of short component
peptides
? Major histocompatability complex (MHC) II molecules located on the
APC surface
? MHC II molecules present this peptides to the T cell receptors
? T cell receptor augmented by additional co stimulatory signals between
the APC and T cell
? Co stimulatory signals including ligation of CD 28,CD 80,CD86( B7-2)
? In the presence of appropriate co stimulation and cytokine environment
navie  CD4+ cells (th0) may be induced to differentiate into T helper
cells I (Th1)or Th2 clones
? Th1 cells are classically associated with cell mediated functions and the
synthesis of complement binding IgG subclasses(Ig G1 and IgG2)
Th 2 cells  are important in the synthesis of non complement binding
antibodies IgG4 and IgE and cytokines secreted by the effector Th1 (IL-2 and
interferon gamma)and Th2 (IL4,5 and 10)clones then direct B cell synthesis of
antibodies, which in the case of FVIII, function as inhibitors.34
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FIGURE.6. FACTOR VIII DOMAINS AND BINDING SITE BY AMINO ACID
LOCATION AND EFFECT ON FACTOE VIII
Factor VIII contains three A domains(A1,A2,A3),one B domain and two
C domains(C1,C2).  Inhibitory antibodies are primarily directed against the
A2,A3 and C2 domains which are the interaction sites of FIX, phospholipids
and von willebrand factor.31 and  interfering with  proteolytic  activation of
FVIII.28 these binding sites are essential for Factor VIII to activate the
coagulation cascade.35 Factor VIII procoagulant levels are inhibited by
inhibitors in several ways including blocking the binding  of  FVIIIa  to  FIXa,
FX . Additionally antibodies that interfere with binding to VWF could displace
FVIII from V in vivo and increase the clearance  of FVIII.32. The formation of
Factor VIII antibodies in patients with haemophilia A occurs because the
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infused Factor VIII is recognised as foreign protein, it will triggering the
immune response.36 Inhibitor is a polyclonal high affinity immunoglobulin G
(IgG) that is directed against  the  FVIII  protein.31. Hemostatic action  of
Factor VIII is inhibited by these inhibitors.36 Predominant one is IgG4 which
do not fix the complement which has been cited as a reason that immune
pathology due to antigen antibody complex is not observed in FVIIII inhibitor
patients.32 Inhibitors developed no tolerance to endogenous FVIII, they may
simply react to  exogenous FVIII as a foreign or non self protein by forming
inhibitor antibodies.37 The only biological function of FVIII is to  become
proteolytically activated and participate as a cofactor for FIXa during intrinsic
pathway factor activation on phospholipids  membranes.32
CLASSIFICATION OF INHIBITORS:
Based on the kinetics and extent of inhibition Inhibitors are classified as
Type I and Type II.31 TYPE I inhibitors follow second order kinetics (dose
dependant linear inhibition) and completely inactivate FVIII, more common in
severe haemophilia. Type II inhibitors have complex kinetics and incompletely
inactivate FVIII even after prolonged incubation.34Type II inhibitors commonly
developed in mild haemophilia or in patients with acquired haemophilia.31
Another classification based on a patient’s peak inhibitor titre after repeated
exposure. The international society on thrombosis and haemostasis scientific
and standardization committee has recommended that an inhibitor titre of 5BU
differentiates low from high responding inhibitors. An antibody titre that is
persistently below 5BU despite repeat challenges with FVIII is considered a
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low responding inhibitor, and the high titre is when the inhibitor assay has been
greater than 5BU at any time. One Bethesda unit is defined as “the amount of
inhibitor that will neutralize 50%of 1 unit of factor VIII:C  in normal plasma
after 2 hrs of incubation at 37°c.13
TABLE.1. CLASSIFICATION OF  INHIBITOR  :
Low response inhibitor inhibitor titre persistently < 5 BU
/ml despite repeated  challenges
with FVIII concentrates.82
High response inhibitors inhibitor titre ?5 at any time.82
Transient disappeared spontaneously after at
least two consecutive positive
detections.82
In the absence of FVIII   exposure, high responding inhibitors may
decrease and may even become undetectable. Classically, when high response
titre patients are re exposed to FVIII, their titre will increase over 4 to 7 days.
This response is anamnesis and is a hallmark of high responding inhibitor. Low
titre inhibitors comprise 25 to 50 % of observed inhibitors and approximately
10% of these are considered transient, disappearing over weeks to months
despite continued treatment with FVIII.36 Haemophilia A patients with a
positive ELISA but undetectable inhibitor levels by Bethesda assay have rarely
been identified indicating the presence of non inhibitory antibodies.32
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ACQUIRED HAEMOPHILIA:
Auto immune bleeding disorder involving the coagulation system occur
as auto antibodies in non haemophiliacs produce a condition called  acquired
haemophilia commonly seen in older age group patients of either sex.32
Incidence of acquired hemophilia is 1to 4 per million/year.39  Very uncommon
condition in children (045per million /year). Incidence of acquired haemophilia
A increases with age (14.7 per million /year). Incidence in men and women is
similar except in the age range of 20 to40 yrs when the effect of pregnancy
results in preponderance in women.39 50% patients have underlying conditions
,including auto immune disorders, malignancy, pregnancy.  Most   haemophilia
A inhibitor (allo antibody) recognize both A2 and C2 domains. in contrast most
auto antibodies recognize either the A2 or C2 domain, but not both, with the C2
domain is frequently affected. Haemarthrosis is rare, but bleeding is more
severe than haemophilia A patients with inhibitor.39
PREVALENCE OF FACTOR VIII  INHIBITORS:
The prevalence of inhibitors is defined as the “proportion of patients
with inhibitors at a specific point in time”. The prevalence of inhibitors is
thought to be about 5-7%. The incidence of inhibitor development is defined as
the number of new cases in a specific period of time. The incidence of
inhibitors in individuals with haemophilia A is estimated to be as high as 33%,
but only 1-6% in patients with haemophilia B. The reason for the difference
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between prevalence and incidence has to do with the disappearance of many
transient low-titre inhibitors and successful tolerization of others.40
RISK FACTORS FOR INHIBITOR DEVELOPMENT IN
HAEMOPHILIA A PATIENTS:
? Genetic mutation :the highest risk is found for null mutations (large
deletion, non sense mutation and the intron 22 inversion)
? Family history of inhibitor
? African or Hispanic race ethnicity
? Immunologic factors include the major histocompatability complex
class ii system and polymorphism of cytokine (interleukins, TNF ?)
TREATMENT RELATED  RISK  FACTORS  :
? Intensity of the first FVIII exposure :surgical procedure, high
frequency treatment
? Source  of  FVIII:  plasma derived versus recombinant factor
products
? Type of therapy   : On demand or prophylaxis
22
TABLE.2.RISK FACTORS   FOR   INHIBITOR   DEVELOPMENT
RISK FACTORS EFFECT REFERENCES
PATIENT RELATED
MUTATION Severe haemophilia.
Highest risks: null
mutation, large deletion,
inversion 1 inversion  22
Oldenburg  (2006)60,
Gouw et al (2011)78,
ETHNICITY 2 to 5 fold increased risk
associated in patients of
Hispanic and African
origin compared with
Caucasians
Viel et al (2009)92
Astermark et al (2001)66
FAMILY HISTORY Increased with first
degree family history ,
Incidence with family
history 48%,Incidence
without family history
15%.
Astermark et al(2001)66
AGE Risk is highest below
the age of 5years and
increases after the age of
60 yrs.
Gouw et al (2007)78
Chalmers et al(2007)42
Santagostino et
al(2005)82
Hay et al(2011)56
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TREATMENT
RELATED
EXPOSURE DAYS:
Risk highest during
early exposure with a
median time of inhibitor
presentation at about 10-
15 EDs. Risk lower after
150 EDs
Lusher et al(1993)65
Shapiro et al (2005)20
Hay et al (2011)56
INTENSE EXPOSURE Risk increased with 5 or
more EDs at first
treatment
Gouw et al (2007)78
Chalmers et al (2007)42
PROPHYLAXIS Early prophylaxis is
associated with a
decreased risk .
Gouw et al (2007)78
TYPE OF
CONCENTRATE
Severe haemophilia A
No evidence of any
difference in inhibitor
risk between
recombinant and plasma
derived concentrate
Franchini and lippi
(2010)19
Aledort et al (2011)
SURGERY Severe haemophilia A
 Risk increased if
surgery combined with
an intensive  first
exposure (>4 ED )
compared to first
exposure without
surgery.
Gouw  et al (2009)78
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GENETIC RISK FOR INHIBITOR DEVELOPMENT:
The important risk factor for development of inhibitor is mutation in
FVIII gene.31   Patients with mutations on their FVIII can generally be divided
into two type 1) Severe molecular defects including null mutations, as the
FVIII proteins  production is completely failed including large
deletions(>1exon),107 non sense mutations, intron 1 and  intron 22 inversion.
2)Milder molecular defects including missense ,small deletion, insertion and
splice site mutation who have loss of function ,but not complete absence of
FVIII protein.39 Chamer’s et al showed the distribution of molecular defects in
the structure of FVIII gene were missense mutation (23%), smalldeletion /
insertion (13%), splicesitemutation (3%) deletions (2%) inversions (56%), stop
mutation (3%).42 Mutations associated with the overall highest rate of (21-
88%) inhibitor formation are null (large deletions, nonsense mutations and
intron 22 inversions). Null mutation in factor gene cannot produce Factor VIII
protein. Among these the most common severe FVIII mutation is intron 22
inversion. The incidence of inhibitor development in null mutation is 21%. The
highest proportion of inhibitor formation (88%) is a seen in large deletion that
involves deletion of multiple domains. missense and splice mutations will
result in loss of function of FVIII, but retain certain production have a lower
risk of inhibitor formation (3-10%).Small deletion or insertions have very low
risk of inhibitor formation.31 Oldenberg et al found that 68.8%of those with
large deletions had higher inhibitors compared with only 21.2% with missense
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mutation and 30% to with all other mutation types.36 Tuddenham et al,
Antonarkis et al ,says ,major loss of coding information and lack major
circulating antigen ,results in 35-40% inhibitors.43
INHIBITOR   DEVLOPMENT ASSOCIATION WITH RACE /
ETHNICITY:
Miller et al says in patients of African or Hispanic descent have an
increased risk of inhibitor formation.31,43 Viel and colleagues demonstrated
the difference in the FVIII  haplotype between patients of african and
recombinant factor VIII . Aster mark et al found African race had two fold
increased risk for inhibitor development compared with white population
reference group.34 Chamer’s et al studied about the role of ethnic origin in
inhibitor development, in his study he showed data on ethnic origin were
recorded for 324 out of 348(93%) patients. Two hundred and sixty-two of
324(81%) were of Caucasian origin while 62 of 324(19%) were non-
Caucasian. Within the non-Caucasian subgroup 64% were of Asian or Arab
origin and only 18% were of African or Hispanic descent. Inhibitor
development was analysed for patients in each ethnic group. In another study
,he showed the overall incidence of inhibitor development in Caucasian
patients was 53 of 262(20%) when compared with 18 of 62 (29%) in non
Caucasians(High titre inhibitors were recorded in 32 of 262 (12%) of
Caucasians and 11of 62 (18%) of non-Caucasians. In a recent Japanese study,
26.8% of patients with haemophilia A developed inhibitor.42. A large Indian
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study of 1285 patients with haemophilia A found that only 6.07% of the
patients had inhibitors, although there were remarkable regional variations (the
highest prevalence was 20.99%.44.
FAMILY HISTORY OF INHIBITOR:
The genes for FVIII  have high rates of mutation and 30% of patients do
not have  family history of hemophilia.45 Charmer’s et al studied about the data
on family history of inhibitor development, he showed  were available for 309
of 348 (89%) patients. Thirty-one of 309 (10%) of patients had a positive
family history of inhibitor development in at least one affected male relative.
Of those with a positive family history, the overall incidence of inhibitor
development was nine of 31 (29%) when compared with 52 of 278 (19%) in
those with a negative family history. High titre inhibitors were recorded in six
of 31 (19%) of those with a positive family history when compared with 31 of
278 (11%) in those with no family history. These figures demonstrated a trend
towards a higher incidence of inhibitor development in those with a positive
family history .42
INHIBITORS ASSOCIATED WITH SEVERITY:
 Commonly the inhibitors   been developed in 25-30% of severe
haemophilia.46 Inhibitors most commonly seen in patients with severe
haemophilia A with incidence of 30%.38 among this 60% high titre (>5BU),
and the remaining are low titre (<5 BU).  Lusher et al says 3-13% occurs in
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mild or moderate haemophilia.31. The risk of inhibitor development depends on
the percentage of circulating Factor VIII activity. The incidence of inhibitor
development is 6 fold higher in patients with large deletions.47 Tuddenham et al
1994 reported that patients with large deletions, stop mutation and inversion
showed that inhibitor incidence of 35%. Missense mutation and small deletions
have 5 to 8 fold lower incidence in inhibitor development like 4.3% and 7.4%
respectively. Mutations which result in a major loss of coding information and
lack of circulating FVIII antigen are all associated with similar, high, 35-
40%prevalence of inhibitors.47. Risk factor for inhibitor formation in mild
hemophilia includes later age with first factor VIII exposure. Intensity of the
FVIII, family history and the type of genetic mutation may influence the
inhibitor development. In mild haemophilia has spontaneous resolution has
been reported in up to 60% cases, after a median of 9 months, however 75% of
patients with spontaneous resolution experienced anamnesis with repeat FVIII
exposure.31. The amount mount of exposure to FVIII is the risk of inhibitor
development in mild haemophilia.32..Severe defects, large deletions in the
FVIII gene ,intron 22 inversions, stop mutations are associated with higher risk
of inhibitor development than small deletions /insertions, missense mutation or
splice site mutations. Patients with severe defects were nearly three times more
likely to develop inhibitors compared  with  patients  with low risk mutation.48
Inhibitor development was more common among patients with severe disease
(39/127; 30.7%), compared to patients with mild disease (4/14; 28.6%).44
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Previously inhibitor development in mild haemophilia is less common than
severe haemophilia.49 With an estimated incidence of 3-13% patients  with
mild haemophilia form inhibitors against the exogenous infused FVIII and
commonly there is inhibitor cross reactivity against  the patients endogenous
FVIII decreasing a patients baseline FVIII level. This decrease changes the
patient phenotype from mild to moderate to severe .Both type I &II inhibitors
are present, there appears to be predominance of type II inhibitors.31
 Sharathkumar et al found inhibitors in milder forms of haemophilia A
more commonly arise under conditions in which the immune system is under
intense stimulation(suggested that continuous infusion may alter the
immunogenicity of the FVIII molecule/or exposure to FVIII is unusually high,
for example in the post operative period). Mutations that result in stable
abnormal conformation in the FVIII   molecules are at particularly high risk for
inhibitor formation in mild haemophilia A Thompson et al says Arg593   ?>
cys mutation is representative of the majority of mild haemophilia inhibitors, in
so far as tolerance to both exogenous and endogenous FVIII is lost36.  Peer
linck et al says the inhibitor from patients with the Arg2150->His mutation
neutralizes exogenous, but not endogenous ,FVIII.34. Risk factors for inhibitor
formation in mild haemophilia   A are
? Intensity of the factor VIII exposure
? Family history of inhibitors
? Types of genetic mutation
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Association between the  Arg 593 Cys genetic mutation and an increased
risk of inhibitor formation .spontaneous resolution has been reported in up to
60 % of cases after a median Of  9 months 75% of patients with spontaneous
resolution experienced anamnesis with repeat FVIII exposure DDAVP should
be used preferentially over factor products in those who are responder.31
Bi model peak of inhibitor risk in early childhood and old age. Inhibitors
develop primarily during early childhood, at the average of 12 yrs.
Development may occur as early as 1 to 2 years typically during the first 20
exposure days when inhibitor risk is greatest.50 The majority of inhibitors
developed during childhood period, at an average age of 12 years, the inhibitor
development occurs in children with severe haemophilia at an average age of 1-
2 years. In severe haemophilia A inhibitors developed at a rate of 6.4 per 1000
years at risk for all ages combined. The rate   varied with age, taking values
34.4, 5.2 and 3.8 per 1000 years at risk at ages <5, 5–14 and 15+years,
respectively. For patients with moderate/mild  haemophilia A the rate of
inhibitor development was just over one quarter that for patients with severe
haemophilia A of similar age91. The mean age at development of inhibitors was
17.7 years (range 6±52 years).51 The age range of patients with haemophilia A
was 1-53 years (median age, 16.0 years).52 Inhibitor formation is commonly
seen in < 5 years age group, rarely seen after 11 years.53 In  children with
severe haemophilia A ,the inhibitor development is highest by the age of 5
years, the cumulative risk reaching 16%,the risk reaches 36% by age 75 yrs.49
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Vast majority (73%) of inhibitors are identified within the first10-20
exposure days to factor concentrates While it is known that most inhibitors
develop within the first 10-20 exposure days .45 Early exposure to FVIII during
the first 6 months of life was associated with a higher incidence of inhibitor
formation.54 Whether early exposure to FVIII is related to inhibitor
development has potentially important implications for the initial management
of infants with haemophilia, particularly those who require treatment at a very
young age. The option of delaying FVIII exposure in young infants was
explored recently by   Rivard et al  in a small pilot study in which the aim was
to use  rFVIIa in place of FVIII until the age of 2 years. Of the 11 infants in this
study, six still required FVIII to control bleeding and four subsequently
developed inhibitors, which suggests that this is unlikely to be a feasible
approach 54,38. The highest risk of developing inhibitors is observed within the
first 50 exposures to FVIII with the risk reducing substantially after 200
treatment days .43,55
IMMUNOLOGIC FACTORS:
Astermark et al  International  Brother Study demonstrated that
polymorphisms of the TNF ?  gene and IL 10 are associated with an increased
risk of inhibitor formation.31 .Explored immunologic factors include the major
histocompatability complex (MHC) class II system and polymorphisms of
cytokines, TNF ? 31 The MHC class II alleles in inhibitor development has a
weak association. Astermark et al evaluated the effect of polymorphism in
immune response genes on inhibitor development, the association of these
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polymorphism with inhibitor formation strongly suggest that, in addition to
lack of self tolerance to FVIII.36.  Polymorphism in the gene coding for IL -
10,TNF ?, Cytotoxic T lymphocyte antigen 4 have been identified as a genetic
factors in the context of Malmo international brother study.43,36 .: Inhibitor
development may occur in conjunction with danger signals presented to the
immune system.32 Injury or inflammation at the time of FVIII exposure to send
danger signals In the danger model, damaged cells send alarm signals that
activate antigen presenting cells, which one amplifying immunologic
responses.  Although  danger model may apply to the overall  result of the
CANAL study, approximately 20% of subjects still developed an inhibitor in
the absence of circumstances that could be associated with these danger
signals.36 Hay et al, Oldenburg et al  demonstrate the association between
inhibitor risk and HLA haplotypes. The HLA DRB1*1501 / DQBI*0602 /
DQAI*0102 haplotype was associated with inhibitors in factor VIII gene intron
22 inversion positive patients and the HLA –DRB1*01 / DQA1*0101 /
DRB1*0501 haplotype associated with inhibitors in intron 22 inversion
negative patient.36 Major histocompatability complex molecules which play a
central role in the cellular cascade leading to antibody formation, have been
evaluated as potential co determinants.48.Two studies detected a weak influence
from MHC i/ii genotypes. No association was found in the MIBS cohort. The
MIBS study also showed that there was a strong association between inhibitor
development and a polymorphism located in the promoter region of the IL-10
gene.57
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RISK FACTORS RELATED TO TREATMENT:
AGE   AT FIRST EXPOSURE TO FACTOR VIII:
In the CANAL cohort study, the risk of inhibitor development in
patients treated with FVIII before the first month of age was 41% compared
with 18% in those who started the treatment after the age of 18 months.48 That
first replacement therapy at an early age may increase the risk of inhibitor
formation.  Lorenzo et al reported that cumulative incidence of inhibitors at 3
years was significantly higher in those initiating therapy before 6 months of age
compared with patients starting with treatment between 6 and 12 months of age
or those treated at age > 12 months (41%vs 29%and 12% respectively) van  der
bom  et al  who reported that the earlier the exposure to FVIII  in infancy (at
the age of 6 months) the higher the risk of developing inhibitors later in life.43.
Recombinant products have an increased risk of inhibitor formation over that
of plasma derived products. The increased immunogenicity to be secondary to
alterations in post translational modifications of FVIII and a lack of von wile
brand binding. in previously untreated patients the inhibitor formation is more
common in recombinant (28.7%) than plasma derived(10.3%).31.Rivard et al
reported that the use of recombinant activated FVIIa on demand in patients
with severe haemophilia A decrease the risk of developing FVIII inhibitors  by
postponing the first exposure to FVIII concentrates until after 2 years of age. 43
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INTENSITY   OF FACTOR VIII AT FIRST EXPOSURE:
The intensity of the  first FVIII exposure  leads to immunologic  danger
signals that stimulate antigen presenting cells and amplify an immunologic
response which could promote inhibitor development.31 The inhibitor
development can be influenced by the circumstances in which FVIII is used, in
Previously untreated, patients(PUP),65% of those in which surgery was the
first indication for FVIII developed an inhibitor compared with approximately
23% in those with other indications for first treatment those who received 5 or
more consecutive days of FVIII  at the time of their first exposure,56%
developed inhibitor, compared with 19%in the group that received fewer than 3
consecutive days of FVII.36  Gouw et al intensive treatment periods (peak
treatment moments, and surgical procedures) were shown to increase  the  risk
of inhibitor formation. Reduced duration between exposure days was
significantly associated with increased risk of inhibitor development.43 The
highest risk of inhibitor development during the first 50 days of exposure .58
Sharathkumar et al found that the incidence of inhibitor development
was more than four times higher in patients administered with full intense
FVIII therapy (administered via continuous infusion) compared with patients
receiving bolus injection (57% vs 14% respectively). 45  Sharathkumar et al in
their retrospective study they found out patients with mild haemophilia who
had received 6 or more consecutive days of FVIII ,inhibitors developed more
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frequently in patients receiving  continuous  infusion compared with bolus
injections(57% vs 0%).36
Less frequent exposure to FVIII concentrate in patients with mild
haemophilia accounted for a lower incidence of inhibitor development CANAL
study ,dose of 35 -50 IU/kg over five consecutive days was associated with 1.4
times the risk than normal dose ,35 IU/kg. This increased to 3.3 times the risk
of a normal dose when FVIII was administered at doses of 50IU /Kg.59
Association between inhibitor development and number of exposure days to
FVIII was also examined in the CANAL Study .Higher number of consecutive
exposure days   increased the inhibitor development in severe haemophilia
patients .In a multicentre cohort study shorter duration between exposure days
increased the risk of inhibitor development. biological   evidence indicates that
higher dose of FVIII will lead to an increased risk of inhibitor development
.Major injuries and surgeries cause tissue damage and inflammation .Damaged
cells from injured areas send danger signals which activate FVIII antigen
presenting cells, up regulating. Co stimulatory signals to T lymphocytes. Both
FVIII expressing antigen presenting cells and T lymphocytes enhance the
formation of antibodies to FVIII in B lymphocytes.
FACTOR VIII  CONCENTRATES:
There are 2 types of Factor VIII concentrates(plasma-derived factors
and recombinant factors), which are associated with varying rates of inhibitor
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formation.42.Availability of different types of  these products, the influence of
the type of Factor VIII concentrate in PUPs with severe haemophilia A is
controversial.60,61,62.The role of  pd FVIII in the  development of inhibitor with
a cumulative incidence of inhibitors ranging from 20.3% to 33.0% in PUPs
exposed to different brands of low or intermediate purity  pd FVIII. 88 Rate of
inhibitor formation in previously untreated patients with haemophilia A were
similar to that observed with full length rFVIII concentrtes.24 In 2006 , Gringeri
and colleagues retrospectively evaluated the occurrence of inhibitors in PUPs
with severe haemophilia A treated with plasma derived VWF containing FVIII
concentrates and found an inhibitor incidence of 9.8%.Several other studies of
patients treated with a single plasma derived high purity  anti haemophilic
factor concentrate  containing  vWF  showed the incidence of inhibitors in the
range from 0% to 12.4%.61,62,63,64  Most of the current high purity pd FVIII
products carry almost 0% risk of inhibitor formation.64.65 There are data
supporting the protective effect of  vWF , a  carrier protein of FVIII which is
present in a large amount in most pd FVIII products , but not in rFVIII. While
study by schwarzinger et al 1987; Rasi &ikala,1990; sultan et al 1992;gave
observations that high purity Factor VIII concentrates caused more inhibitors
than traditional intermediate purity products.74. Inhibitor development was most
common in the recombinant subgroup (14/43; 32.6%), which was followed by
the plasma-derived subgroup (19/59; 32.2%), the group with multiple products
(6/22;27.3%), and the fresh frozen plasma group (4/18; 22.2%). However,
these differences were not statistically significant (P=0.883).Inhibitor
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development is lower than patients treated with low purity and intermediate
purity.32 Plasma-derived FVIII concentrates might be associated with a lower
incidence inhibitor development due to the protective effect of their von
willebrand factor which would  mask  the epitope sites of inhibitors on the
FVIII molecule or would prevent FVIII  endocytosis by dendritic cells.58 Gouw
et al  in his study ,he reported that no difference between low von willebrand
factor content and high von willebrand factor content.25 Recombinant products
are available in different generation which are First-generation recombinant
FVIII products . The recombinant FVIII concentrates that use animal-derived
proteins in the cell culture medium and have human serum albumin added to
stabilize the final formulation. Second-generation recombinant FVIII products:
The recombinant FVIII concentrates that use animal-derived proteins in the cell
culture medium but have no human serum albumin added to the final
formulation .58 The incidence of inhibitor formation in PUPs with severe
hemophilia  A ranges from 2.7% to was51.8% with plasma-derived FVIII and
from 7.7% to 41.9% with recombinant FVIII concentrates .No statistically
significant differences in cumulative inhibitor rate were found between plasma-
derived FVIII and any recombinant FVIII preparations.58 Rates were higher in
patients treated with first-generation recombinant FVIII (0.31; 95% CI, 0.25–
0.37) than among those treated with second-generation recombinant FVIII
products (0.18; 95% CI, 0.09–0.31). We also found a higher prevalence of
inhibitors among patients who were receiving recombinant factors, and this
result agrees with the findings from our previous studies.42
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Meta-analysis conducted by   Iorio and colleagues 87. These authors
identified 2094 patients, from 24 retrospective and prospective studies, among
whom 420 developed inhibitors. The pooled incidence inhibitor rate was 14.3%
for plasma-derived FVIII concentrates and 27.4% for recombinant FVIII
products (p < 0.001), although the difference lost statistical significance at
multivariate analysis.  Franchini et al was observed similar results when the
analysis was restricted to the 19 prospective studies (9.1% for plasma derived
FVIII concentrates and 23.7% for recombinant FVIII products, p < 0.001).66 By
contrast, their meta-analysis showed a non-statistically significant difference
(weighted means, 21% with plasma-derived FVIII versus 27% with
recombinant FVIII products) in inhibitor incidence. Recombinant products
have an increased risk of inhibitor formation over that of plasma derived
products.31The increased immunogenicity to be secondary to alterations in post
translational modifications of FVIII and a lack of von wile brand binding. In
previously untreated patients the inhibitor formation is more common in
recombinant (28.7%) than plasma derived(10.3%).31 Also in the meta-analysis
by Iorio and colleagues, the statistical significance in inhibitor incidence
between prospective studies involving plasma-derived or recombinant FVIII
concentrates disappeared when only high-titre inhibitors were considered
(6.0% with plasma-derived FVIII versus 19.4% with recombinant FVIII
products, p = 0.195). This meta analysis showed the lowest inhibitor incidence
rate (11%) was found with the second generation recombinant FVIII
concentrate.
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MODE OF  TREATMENT  :   PROPHYLAXIS  AND  ON DEMAND
‘The definition of prophylaxis is the regular infusion of factor VIII
concentrate with the aim of preventing bleeding, starting within first two years
of life’.67 Several different prophylaxis regimen, which are differentiated by
dose and frequency of factor administration. Malmo regimen full dose
prophylactic regimen involves administration of 25 to 40 U/kg of FVIII every
other day (minimum 3 days /week).the “intermediate –dose” prophylactic dose
regimens involves the administration of 15 t0 25 U/kg two or three times a
week.  Low dose prophylactic regimen involves 10 to 15 U/ kg  given  one or
two times a week.
TABLE.3.TREATMENT REGIMEN
Full dose regimen 25 to 50U/kg ,3days(every other day) /
week
Intermediate dose regimen 15 to 25 U/kg two to three times /week
Low dose prophylaxis 10 to 15 U/kg one or two times/week
Prophylaxis regimens reduce the risk of inhibitor development
compared with bolus on demand treatment in terms of exposure to FVIII
.Owing to the similarities in terms of genetic mutations and age in the
prophylaxis  and  on  demand  groups , the author concluded that on demand
therapy represents a clear risk  factor for the development d of inhibitors. An
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univariate analysis was used to demonstrate that commencing prophylaxis
before the age 35 months carried an inhibitor risk of 28% compared with 56%
risk in patients with on demand therapy. Danger theory of tolerance proposes
that the immune system responds to danger signals from both exogenous and
endogenous sources. If an antigen is not itself   perceived as dangerous  and no
other danger signals- such as cell necrosis or tissue injury are present ,tolerance
normally occurs rather than an immune response. prophylactic regimen may
offer a protective regimen offer a protective effect since the patient is treated in
the absence of any additional danger signals, whereas on demand
administration of FVIII may be perceived as dangerous doe to danger signals
from ongoing bleeding episodes or during physiological stress such as
surgery.48 The prophylactic treatment was initiated in Sweden to prevent the
bleeding episodes and minimizing the impact of arthropathy.10 According to
WHO&WFH   starting the prophylactic treatment for the child with severe
haemophilia At an early age is the optimal therapy.” Scientific and
standardization committee (SSC) of the International Society on Thrombosis
and haemostasis (ISTH)   defines   the primary prophylaxis is a continuous
therapy starting after the first joint bleed and before the age of 3 years”.
Secondary prophylaxis can either   be continuous long term treatment started
after two or more joint bleeds or after the age of 3 years. Manco- Johnson et al
showed the median haemorrhages of children undergoing prophylactic
treatment was 1.2, compared with 17.1 in on demand group. Aster mark et al
suggested if the prophylaxis was started before two years of age, significantly
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reduce the joint damage. The risk of ICH is 20-50 times higher in a person with
hemophilia who is on demand therapy.  Starting the treatment as prophylaxis or
the first 20 exposure days have a decreased risk to develop inhibitors compared
to on demand therapy. Even though the patient receiving the prophylaxis
during the first 20 exposure days ,the inhibitors will develop ,because of the
type of mutation, family history of inhibitors  and other genetic risk factors.
SPINART study compared the on demand therapy and prophylactic based on
the total  bleeding episodes per year(27.9 versus 0), the median number of total
bleeding episodes(54.5 versus 0), study showed the bleeding episodes  were
significantly lower with prophylaxis than with on demand treatment . Primary
prophylaxis was successfully pioneered in Sweden and then adopted in other
countries, achieving the goal of preventing the majority of bleeding episodes
and further reducing the impact of arthropathy.68
DIAGNOSIS AND INVESTIGATIONS OF   FACTOR VIII
INHIBITORS:
Inhibitor is suspected when a patient has a poor clinical response to
concentrate or lower FVIII levels than expected after concentrate infusion. it is
crucial to detect the inhibitor as early as possible is to minimize anamnesis
response , limit the unnecessary exposure to sub optimal treatment, if the
inhibitor does not rise above 10 BU /ml, allow immune toleration induction to
be started without delay .
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INHIBITOR TESTING IS REQUIRED:
? before elective invasive procedures when the clinical response to
concentrate is sub optimal
? before and after switch of concentrate
? 2-3 weeks after intensive treatment (?5EDs)
? If any surgery is going to be performed for mild or moderately affected
patients
INHIBITOR SCREENING FOR SEVERE HAEMOPHILIA A:
? At least every third ED or every 3 months if concentrate exposure has
occurred (whichever is sooner) until 20 EDs have been achieved
? After that every 3-6 months until 150 EDs
? Inhibitors may occur at any age and incidence increases again after the
age of 60 years therefore testing should continue 1-2 times a year
indefinitely
INHIBITOR SCREENING FOR MILD/ MODERATE HAEMOPHILIA A
? Should be tested annually if exposed to concentrate
? After any intensive exposure (?5 EDs)
? Surgery
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TREATMENT FOR   HAEMOPHILIA   A PATIENTS WITH
INHIBITOR
Aim of the treatment is to achieve a therapeutic level of FVIII to
maintain the haemostasis. Choice of   treatment   product   based on titre of
inhibitor ,clinical response to product.
FOR LOW TITRE INHIBITOR:
Patients with a low titre inhibitor may be treated with factor replacement
at  a  much higher dose, to neutralize the inhibitor with excess factor activity
and stop bleeding..9
FOR HIGH TITRE INHIBITOR:
Kurczynski and penner used an Factor VIII bypassing agents (FEIBA),
prothrombin complex concentrate (PCC) to circumvent the hemostatic
requirement for FVIII . 1975 ,the PCCs contain more concentration of FVII
,showed more effectiveness than the products contains lower concentration of
FVII .Since activated factors in the PCCs were thought to be responsible for the
hemostatic effect. Then activated PCCs were prepared by “controlled
activation” of the original unactivated prothrombin complex concentrate.
During preparation the Factor VII is activated to factor VIIa. Factor VIIa in the
activated PCCs was considered to be the major bypassing agent. Difficulty in
preparing the plasma derived Factor VIIa, resulted in the development of
recombinant factor VIIa (rFVIIa).The half life of  rFVIIa to be 2.60 to 2.84
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hours.70 Lisman and De Groot et al describes the Mechanism of  action  of
FVIIa as bypassing agent .They said  tissue factor pathway is required for
rFVIIa will bind to activated platelets and directly activate  FX to FX, this
mechanism not only accelerates the clot formation also inhibits  fibrinolysis  by
activation of thrombin  activatable  fibrinolytic inhibitor (TAFI) .The
recommended dose is 90µg/kg given intravenously every 2 hrs until bleeding
stops.70 Prophylaxis  with daily doses of rFVIIa shown to decrease spontaneous
joint bleeds. Monitoring of rFVIIa with either thromboelastography or the
thrombin generation  is necessary.
IMMUNE TOLERANCE INDUCTION:
The induction of immune tolerance (IIT), pioneered by H.H
Brackman.27 Before immune tolerance induction  therapy ,high responding
patients should avoid FVIII products, to allow inhibitor titres to fall and to
avoid persistent anamnestic response.9   Repeated   doses of FVIII  concentrate,
along with infusions  of prothrombin complex concentrate, were given until the
inhibitor disappeared and the half life of FVII was normalized .5-10% of the
inhibitors persist even after the immune tolerance induction, render the patients
resist to Factor viii replacement.56 International Immune Tolerance Registry
(IITR) describes the factor influencing the outcome of immune tolerance
induction are ,the daily factor VIII dose ? 200IU/Kg/day was  associated  with
more favourable outcome, particularly in patients with inhibitor titre >10BU/ml
. The success rate with current regimens is in the 70±10%.
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MATERIALS AND METHODS
This is a cross sectional study done on patients who were diagnosed as
Haemophilia A  attending Department of Medicine, Royapettah Government
General Hospital and the laboratory work up was done at Department of
Transfusion Medicine The TN Dr M.G.R Medical University.
Aim of our study is to find out the prevalence of   Factor VIII inhibitors
in haemophilia A patients those who are receiving plasma derived Factor VIII
therapy. The study was done over a period of one year from July 2016 to June
2017.During this period we studied a total of 90 patients with haemophilia A .
Factor VIII level estimation, inhibitor screening assay and   Bethesda assay was
done at Department of Transfusion Medicine The TN Dr M.G.R Medical
University.
STUDY POPULATION:
Patients with Haemophilia A  who  were diagnosed on the basis of
clinical features and Factor VIII assay and received plasma derived Factor VIII
and blood components (FFP and cryoprecipitate) were included in our study.
The study protocol was approved by the ethical committee of The TN Dr
M.G.R Medical University and Ethical committee of Kilpauk Medical College.
Sample size was calculated by using the formula Z? (1/2)2 Pq/d2.. According to
the formula the sample size was 90.
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INCLUSION CRITERIA:
All patients  those who were diagnosed as haemophilia A and receiving
plasma derived Factor VIII therapy in the  Hemophilia  treatment  centre  at
Royapettah  Government general hospital.
EXCLUSION CRITERIA:
Patients those who are diagnosed as hemophilia B, already inhibitor
developed patients those who are on rFVII   therapy and the patients who are
not willing to participate in the study are excluded.
METHODOLOGY:
Complete details regarding the patient which includes name,  age , sex,
gender, IP number, clinical diagnosis of the patient and the history related to
family history of haemophilia A, family history of inhibitor and the  treatment
history including  age at which exposed to Factor VIII, number of exposures to
Factor VIII, interval between the exposure days, dose of Factor VIII given were
obtained by questionnaire given to the patient. The laboratory work up
including the quantitative assessment of Factor VIII, mixing study and the
inhibitor screening was done for the patients those prolonged aPTT was not
corrected by mixing study, then quantitative assessment of inhibitors (Bethesda
study) by using the coagulation analyser named Hemostar 2 channel (from
Tulip diagnostics) were done at  Department of Transfusion Medicine, The TN
Dr M.G.R Medical  university .
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SAMPLE COLLECTION:
3 ml venous blood sample was collected in citrate tubes (3.2% tri
sodium citrate). The blood was mixed with sodium citrate anticoagulant in
proportion of blood to citrate as with 9:1.sample was collected within one
minute of tourniquet application without much venous stasis and sample was
processed immediately. Platelet poor plasma (PPP) was prepared by double
centrifugation of a sample at 1700 g for 10 mts at room temperature.  Test was
done within four hours of collection. If any delay to perform the  test , the
platelet poor plasma can be frozen at -30°C for 2 months or up to 6 months if
stored at -70°C9.For transportation the sample should be shipped in dry ice
(-70°c) to maintain the sample frozen for the required transport time.19
PROCEDURE:
APTT
? Pre warm  APTT  reagent(Liquecelene E, Tulip diagnostics) ,CaCl2 at
37°c for at least 10 minutes
? Pipette 100µl of test  plasma into test  cuvette
? Incubate exactly for 1 minute
? Add 100 µl  APTT reagent and incubate exactly for 3 minutes
? Add 100 µl  CaCl2
? Record the clotting time in seconds
? Normal range :28-36 seconds
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FACTOR VIII ASSAY
One-stage FVIII: C Assay
? Pipette 100µl  of  test plasma and 900 µl of Owren’s Veronal Buffer into
test cuvette
? Take 100µl of diluted test plasma, add 100 µl Factor VIII deficient
plasma(Factor VIII deficient plasma ,1 ml, Tulip diagnostics) and start
test
? Incubate exactly for 1 min
? Add 100 µl APTT reagent
? Incubate exactly for 3 min
? Add 100 µl CaCl2 record the value in percentage.
? Prepare and run the standards
? Plot clotting time obtained with each standard dilution against % activity
using log – log graph
? Factor VIII concentration is expressed in iµ /l or % activity
MIXING STUDY:
? Take 100µl of test plasma, add  equal volume (100µl) of  pooled normal
plasma
? Keep the mixture for incubation at 37°c water bath for 2 hrs
? Run the aPTT test for this incubated mixture of test plasma and  pooled
normal plasma
? If the  aPTT  is prolonged, and normal plasma fails to correct the APTT
,an inhibitor should be suspected.4,13
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INHIBITOR SCREENING:
REQUIRMENTS:
? Pooled Normal plasma
? Test Plasma
? Reagents for APTT ,Calcium Chloride
Method
? 3 Plastic Tubes are prepared – A,B and C
? Put 0.5 ml normal plasma into tube A,
? 0.5 ml test plasma into tube B and
? 0.5 ml each of normal and test plasma into tube C
? Incubate for 60 minutes at 370C in water bath
? Make a 50:50 mix from tubes A and B – this is tube D, fresh mix
? Perform an APTT in duplicate in tube no C, incubated mix
? Perform an APTT in duplicate in tube no D, fresh mix
? If negative result, repeat the test at the end of 2 hour
? Results/Interpretation
? If Difference between fresh mix and incubated mix is more than 5 sec
indicates the presence of inhibitors. If inhibitor screen positive proceed
to inhibitor assay.10
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FACTOR VIII INHIBITOR ASSAY (BETHESDA ASSAY)
Principle:
A Bethesda unit is defined as the amount of inhibitor which will
neutralise 50% of one unit of added factor VIII: C in normal plasma after 2
hours of incubation at  370C .13
Requirements :
? Owren’s Buffered Saline  with   pH (7.4)
? Pooled  normal  Plasma
? Calcium Chloride
? Factor VIII deficient plasma
? APTT reagent
? Prepare doubling dilutions (1/2, 1/4, 1/8, 1/16, ... up to 1/1024) of test plasma in
plastic tubes in 150 µl volumes using Owren’s buffer as diluents.
? Label 12 glass tubes
? Tube 1 - 150µl control pnp + 150µl of buffer
? Tube 2 - 150µl test plasma + 150µl of control plasma
? Tube 3 – 12- 150µl of respective diluted test plasma from ( 1/2   - 1/1024 ) +
150µl of control plasma in all tubes.
? Cap, mix by inversion and incubate all tubes at 370C for 2 hours
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? Perform a Factor VIII assay on all incubation mixtures by the usual
factor VIII assay method but use the tube setup as standard as 100 %
activity.
RESULTS / INTERPRETATION:
Calculation of Inhibitor Level :
? Factor VIII activity of the control and the patient incubation mixtures
are determined from Factor VIII assay curve.
? Residual Factor VIII activity is determined using the Factor VIII activity
of the control and dilution of patient plasma having a Factor VIII
activity that yields a residual Factor VIII activity greater than 25% lesser
than 50%.
Residual Factor VIII activity = Factor VIII activity(patient)  x 100
                                                   Factor VIII activity (control)
? Residual Factor VIII activity is converted to BETHESDA UNIT Factor
by using a  standard   chart.
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The Y axis is a log scale and the X axis is a linear. Residual   FVIII is
plotted on the Y log axis and BU titre on the linear X axis .Derive the inhibitor
titre from the graph and multiply by the dilution to give the final titre.
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RESULTS:
Table .4.DISTRIBUTION  OF PATIENTS ACCORDING TO SEVERITY
CLASSIFICATION FREQUENCY PERCENT (%)
Mild 4 4.4
Moderate 27 30.0
Severe 59 65.6
Total 90 100.0
Figure.7.Classification based on Severity
Patients with haemophilia A were classified into 3 groups based on the
FVIII levels.. In our study out of 90 patients , 59(65.6%)were in the severe
group, followed by 27(30%),4(4.4%) patients in moderate group and in the
mild group respectively.
4.4
30
65.6
CLASSIFICATION BASED ON SEVERITY
MILD
MODERATE
SEVERE
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Table.5. DISTRIBUTION OF AGE OF DIAGNOSIS ACCORDING TO
SEVERITY
Age of
diagnosis
Mild Moderate Severe p value
<1year 0 4 31
0.000
1-6years 1 14 25
7-14years 1 4 2
>14 years 2 5 1
FIGURE.8.AGE OF DIAGNOSIS ACCORDING TO SEVERITY
Out of 90 patients screened, 59   were Severe  haemophilia . Out of 59,
31 were diagnosed before 1year of age .Out  of  27  moderate  haemophilia  A
patients  4 were diagnosed before 1year of age group. All (4) mild hemophilia
patients were diagnosed after 1 year of age group. This association is
statistically significant with p value of 0.000.
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Table.6 .ASSOCIATION BETWEEN FAMILY HISTORY OF
HAEMOPHILIA   A  & SEVERITY OF HEMOPHILIA  A
Family
history
Mild Moderate Severe
Pvalue
0.004
Frequency % Frequency % Frequency %
YES 2 3.84% 9 17.30% 41 78.84%
NO 2 5.26%% 18 47.36% 18 47.36%
FIGURE.9.FAMILY HISTORY ACCORDING TO SEVERITY
Family history of haemophilia A was highest among in severe
haemophilia A   patients. This   association   was statistically significant with
p value of 0.004.
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CLINICAL MANIFESTATIONS OF HAEMOPHILIA A PATIENTS &
ASSOCIATION WITH SEVERITY:
Table.7. SPONTANEOUS BLEEDING & SEVERITY OF
HAEMOPHILIA A
Spontaneous
bleeding
Mild Moderate Severe
p.value
0.000
Frequency % Frequency % Frequency %
YES 0 0% 17 22.4% 59 100%
NO 4 100% 10 71.4% 0 0%
FIGURE.10.SPONTANEOUS BLEEDING & SEVERITY OF
HAEMOPHILLIA A
All severe haemophilia A Patients had the history of spontaneous
bleeding. This   is  statistically significant with p value of 0.000.
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Table.8.GUM BLEEDING & SEVERITY OF  HAEMOPHILIA  A
Gum
bleeding
Mild Moderate Severe
p
value
. 223
Frequency % Frequency % Frequency %
YES 3 3.7% 24 29.3% 55 67.1%
NO 1 12.5% 3 37.5% 4 50.0%
FIGURE.11.GUM BLEEDING & SEVERITY OF HAEMOPHILIA  A
Out of 59 severe haemophilia A  patients , 55(67.1%) had history of
gum bleeding ,followed by moderate (29.3%),and mild (3.7%) haemophilia A.
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Table.9.ASSOCIATION  BETWEEN  PATIENTS WITH EPISTAXIS &
SEVERITY OF  HEMOPHILIA  A
Epistaxis
Mild Moderate Severe p
value
0.025
Frequency % Frequency % Frequency %
Yes 1 2.3% 9 20.5% 34 77.3%
No 3 6.5% 18 39.1% 25 54.3%
FIGURE.12.EPISTAXIS &SEVERITY OF HAEMOPHILIA A
Out of 90 patients were   screened , 44 had the history of Epistaxis.
Among the 44, 34 (77.3%) belonged   to severe   haemophilia   A, followed by
moderate (20.5%) and mild haemophilia A (2.3%).
This association is statistically significant with p value of 0.02.
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Table.10. ASSOCIATION BETWEEN PATIENTS WITH
HEMARTHROSIS & SEVERITY OF HEMOPHILIA   A
Hemarthrosis
Mild Moderate Severe
P
value
0.008
Frequency % Frequency % Frequency %
YES 2 2.3% 26 30.2% 58 67.44%
NO 2 50% 1 25% 1 25%
FIGURE.13.HEMARTHROSIS& SEVERITY OF HAEMOPHILIA  A
In our study group, hemarthrosis was highest among severe group. This
association is statistically significant with p value of 0.008.
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Table.11. ASSOCIATION BETWEEN PATIENTS WITH HEMATOMAS
& SEVERITY OF HAEMOPHILIA A
Hematomas
Mild Moderate Severe
p
value
0.112
Frequency % Frequency % Frequency %
YES 2 2.7% 21 28.8% 50 68.5%
NO 2 11.8% 6 35.3% 9 52.9%
FIGURE.14.HEMATOMAS &SEVERITY OF HAEMOPHILIA  A
Among the 59 severe haemophilia A patients, 50 (68.25%) had
hematomas, followed by moderate (28.8%) and mild (2.7%) haemophilia A.
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Table.12.  ASSOCIATION BETWEEN PATIENTS WITH HEMATURIA
& SEVERITY OF HAEMOPHILIA A
Hematuria
Mild Moderate Severe
p
value
0.000
Frequency % Frequency % Frequency %
YES 1 2.5% 3 7.5% 36 90.0%
NO 3 6.0% 24 48.0% 23 46.0%
FIGURE.15.HEMATURIA &SEVERITY OF HAEMOPHILIA A
In our study group, hematuria was highest among the severe
haemophilia A patients.
This association is statistically significant with p value of 0.000.
1
3
36
3
24 23
0
5
10
15
20
25
30
35
40
MILD MODERATE SEVERE
H
E
M
AT
U
R
IA
SEVERITY OF HEMOPHILIA  A
YES
NO
61
Table.13. ASSOCIATION BETWEEN PATIENTS WITH UMBILICAL
BLEED &  SEVERITY  OF  HAEMOPHILIA  A
Umbilical
bleed
Mild Moderate Severe
p
value
0.114
Frequency % Frequency % Frequency %
YES 0 0% 0 0% 5 100%
NO 4 4.7% 27 31.8% 54 63.5%
FIGURE.16.UMBLICAL STUMP BLEED &SEVERITY
OFHAEMOPHILIA A
Among the 90 haemophilia A   patients ,only 5 patients  had umbilical
stump bleeding. All the 5 patients   were   diagnosed as severe haemophilia A.
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Table.14. ASSOCIATION BETWEEN RETROPERITONEAL
BLEEDING & SEVERITY OF HAEMOPHILIA A
Retroperitoneal
bleed
Mild Moderate Severe
p
value
0.003
Frequency % Frequency % Frequency %
YES 0 0% 1 5.8% 16 94.1%
NO 4 5.4% 26 35.6% 43 58.9%
FIGURE.17.RETROPERITONEAL BLEED &SEVERITY OF
HAEMOPHILIA A
In our study group, Out of 90 patients 17 patients had retroperitoneal
bleed, among 17 patients , 16 were  diagnosed as severe haemophilia A.
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Table.15. ASSOCIATION BETWEEN PATIENTS WITH INTRA CRANIAL
HEMORRHAGE (ICH) & SEVERITY OF HAEMOPHILIA  A
ICH
Mild Moderate Severe
p
value
0.427
Frequency % Frequency % Frequency %
YES 0 0% 0 0% 2 100%
NO 4 4.5% 27 30.7% 57 64.8%
FIGURE.18.INTRA CRANIAL HEMORRHAGE & SEVERITY OF
HAEMOPHILIA A
Out of 90 patients, 2 patients had intra cranial hemorrhage.
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INHIBITORS IN HAEMOPHILIA A   PATIENTS
Table.16. PREVALENCE OF INHIBITORS IN HAEMOPHILIA A PATIENTS
Inhibitor Frequency Percentage
Positive 3 3.3%
Negative 87 96.7%
FIGURE .19.PREVALENCE OF INHIBITORS
Out of 90 patients were screened, 3 (3.3%) were found to have
developed inhibitors, while 87(96.7%) did not develop inhibitors.
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inhibitorpositive
inhibitor negative
65
Table.17.PREVALENCE OF LOW AND HIGH TITRE INHIBITORS
    Inhibitor Frequency Percentage
Negative 87 96.7
High titre 1 1.1
Low titre 2 2.2
Total 90 100
FIGURE.20.LOW TITRE & HIGH TITRE INHIBITOR
Out of 3 (3.3%) patients positive for inhibitor development, one (1.1%)
was high titre inhibitor positive and two(2.2%) were low titre inhibitor positive.
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Table.18. ASSOCIATION BETWEEN INHIBITOR  DEVELOPMENT
&SEVERITY OF   HAEMOPHILIA  A
Inhibitor
Mild Moderate Severe
Frequency % Frequency % Frequency %
POSITIVE 0 0% 0 0% 3 5.1%
NEGATIVE 4 100% 27 100% 56 62.2%
FIGURE.21.INHIBITOR &SEVERITY OF HAEMOPHILI A
All patients who developed inhibitors belonged to Severe haemophilia,
which is in accordance with finding that inhibitors develop more commonly in
Severe haemophilia group.
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Table.19. ASSOCIATION BETWEEN INHIBITORS & FAMILY
HISTORY OF HAEMOPHILIA A
Family H/o
Haemophilia
Inhibitor Positive Inhibitor Negative
p value
0.132
Frequency Percent Frequency Percent
Positive 3 5.7% 49 94.3%
Negative 0 0.0% 38 100%
FIGURE.22.INHIBITOR &FAMILY H/O HAEMOPHILIA A
All 3 inhibitor developed   patients had positive family history of
haemophilia A.
3
0
49
38
0
10
20
30
40
50
60
YES NO
IN
H
IB
IT
O
R
FAMILY HISTORY  OF HEMOPHILIA  A
INHIBITOR POSITIVE
INHIBTOR NEGATIVE
68
Table.20. ASSOCIATION BETWEEN FAMILY HISTORY OF
INHIBITORS & INHIBITOR DEVELOPMENT
Family H/o
inhibitors
Inhibitor Positive Inhibitor Negative
p value
.007
Frequency % Frequency %
YES 2 40.0% 3 60.0%
NO 1 1.2% 84 98.8%
FIGURE.23.INHIBITOR & FAMILY H/O INHIBITOR
Out of 3 patients who developed  inhibitors , 2 had positive family h/o
inhibitors.
This association was statistically significant with p vale of 0.007.
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Table.21. ASSOCIATION BETWEEN CONSANGUINITY &
INHIBITORS DEVELOPMENT
Consanguinity
Inhibitor positive Inhibitor negative
p
value
.474
Frequency Percentage Frequency Percentage
YES 1 6.3% 15 93.8%
NO 2 2.7% 72 97.3%
FIGURE.24.INHIBITOR &CONSANGUINITY
Among patients (16) born out of consanguineous marriage, one (6.3%)
developed inhibitor.
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ASSOCIATION BETWEEN CLINICAL MANIFESTATIONS AND
INHIBITOR DEVELOPMENT
Table. 22. ASSOCIATION BETWEEN PATIENTS WITH
SPONTANEOUS BLEEDING & INHIBITOR DEVELOPMENT
Spontaneous
bleeding
Inhibitor Positive Inhibitor Negative
p value
.455
Frequency Percentage Frequency Percentage
YES 3 3.9% 73 96.1%
NO 0 0 14 100%
FIGURE.25.INHIBITOR & SPONTANEOUS BLEEDING
All 3 inhibitor positive patients had history of spontaneous bleeding.
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Table.23. ASSOCIATION BETWEEN PATIENTS WITH
UMBILICAL STUMP BLEEDING & INHIBITOR DEVELOPMENT
Umbilical
stump bleed
Inhibitor Positive Inhibitor Negative
p value
.033
Frequency Percentage Frequency Percentage
YES 1 20% 4 80%
NO 2 2.4% 83 97.6%
FIGURE .26.INHIBITOR &UMBILICAL STUMP BLEEDING
Among the 90 patients , 5 patients  had the history of umbilical bleed,
one developed inhibitor.
     This association was statistically significant with the p value of 0.033.
20%
2.40%
80%
97.60%
0%
20%
40%
60%
80%
100%
120%
yes no
IN
H
IB
IT
O
R
UMBILICAL STUMP  BLEED
INHIBITOR NEGATIVE
INHIBITOR POSITIVE
72
Table.24. ASSOCIATION BETWEEN PATIENTS WITH  HEMATURIA
& INHIBITOR   DEVELOPMENT
Hematuria
Inhibitor Positive Inhibitor Negative
p value
.050
Frequency Percentage Frequency Percentage
YES 3 7.5% 37 92.5%
NO 0 0% 50 100%
FIGURE.27.INHIBITOR & HAEMATURIA
Out  of  90  patients , 40 patients  had the history of  hematuria, among
them 3 patients were developed inhibitor.
This association was statistically significant with the p value of 0.05.
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Table.25. ASSOCIATION BETWEEN INTRA CRANILA
HEMORRHAGE (ICH)  & INHIBITOR DEVELOPED PATIENTS :
ICH
Inhibitor Positive Inhibitor Negative
p value
0.000*
Frequency Percentage Frequency Percentage
YES 1 50% 1 50%
NO 2 2.3% 86 97.7%
FIGURE.28.IHIBITOR &INTRA CRANIAL HAEMORRHAGE
Among   the  90 patients ,2 patients had the history of intra cerebral
hemorrhage.1 (50%)  patient developed inhibitors.
 This   association was statistically significant with the p value of 0.000.
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Table.26.  ASSOCIATION BETWEEN CRIPPLING ARTHROPATHY &
INHIBITOR DEVELOPED PATIENTS
Crippling
arthropathy
Inhibitor  Positive Inhibitor     Negative p value
.033Frequency Percentage Frequency Percentage
YES 1 20% 4 80%
NO 2 2.4% 83 97.6%
FIGURE.29. INHIBITOR & CRIPPLING ARTHROPATHY
Out of 90 patients,5  patients had the history of crippling arthropathy,
among the 5 patients, one  patient developed inhibitor.
This association is statistically significant with p value of 0.033.
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ASSOCIATION BETWEEN TREATMENT RELATEDRISK
FACTORS & INHIBITOR
Table.27. ASSOCIATION BETWEEN INHIBITOR DEVELOPMENT &
AGE AT WHICH FVIII EXPOSURE
Age at which
exposed to
FVIII
Inhibitor Positive Inhibitor Negative
p value
.791
Frequency Percentage Frequency Percentage
<6 months 0 0% 2 100%
>6 months 3 3.4% 85 96.6%
FIGURE.30. ASSSOCIATION BETWEEN INHIBITOR & AGE AT
WHICH FACTOR VIII EXPOSED.
Relatively high frequency of inhibitor positivity was found in patients
who received their first factor VIII transfusion after the 6 months of age group
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Table.28. ASSOCIATION BETWEEN INHIBITOR DEVELOPMENT &
NUMBER OF FVIII   EXPOSURES
No. of  times
Factor VIII
Exposures
Inhibitor     Positive Inhibitor Negative
p value
.331
Frequency Percentage Frequency Percentage
<50 0 0% 21 100%
>50 3 4.3% 66 95.7%
FIGURE.31.ASSOCIATION BETWEEN INHIBITOR &NUMBER OF
EXPOSURES TO FACTOR VIII
Inhibitor were seen to develop in patients with exposure to Factor VIII
>50 times.
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Table.29. ASSOCIATION BETWEEN INHIBITOR DEVELOPMENT &
DOSE OF FVIII
Dose of
FVIII
Inhibitor Positive Inhibitor Negative
p value
.000
Frequency Percentage Frequency Percentage
>50IU/Kg 3 50% 3 50%
<50iu/kg 0 0% 84 100%
FIGURE.32.ASSOCIATON BETWEEN INHIBITOR &
DOSE OF FACTOR VIII
Out of 90  patients , 6 were treated with >50IU/Kg .among the 6
patients, 3 had developed inhibitors.
This association was statistically significant with p value of 0.000.
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Table.30. ASSOCIATION BETWEEN INHIBITOR DEVELOPMENT&
INTERVAL BETWEEN EXPOSURE DAYS
Interval
between
exposure days
Inhibitor Positive Inhibitor Negative
p value
.000
Frequency percentage Frequency Percentage
<10 3 75% 1 25%
>10 0 0% 86 100%
FIGURE.33.ASSOCIATION BETWEEN INHIBITOR &INTERVAL
BETWEEN EXPOSURE DAYS
4 patients had the  interval between 5 consecutive exposure days is less
than 10 days , out of 4 patients 3 had developed inhibitor.
This association was statistically significant with the p value of 0.000.
3 01
86
0
10
20
30
40
50
60
70
80
90
100
<10 >10
IN
H
IB
IT
O
R
Interval Between 5 Consecutive Exposure Days
inhibitor positive
inhibitor negative
79
1 24
83
0
10
20
30
40
50
60
70
80
90
YES NO
IN
H
IB
IT
O
R
SURGERY WITHIN 50 EXPOSURE DAYS
INHIBITOR POSITIVE
INHIBITOR NEGATIVE
Table.31. ASSOCIATION BETWEEN DEVELOPMENT OF
INHIBITORS & SURGERY WITHIN 50 DAYS OF EXPOSURE
Surgery
within 50
days of
exposure
Inhibitor Positive Inhibitor     Negative
p value
0.159
Frequency Percentage Frequency Percentage
YES 1 20% 4 80%
NO 2 2.4% 83 97.6%
FIGURE.34.ASSOCIATION BETWEEN INHIBITOR &SURGERY
WITHIN 50 EXPOSURE DAYS
In 5 patients who had major surgeries within 50 days of exposure, 1
developed inhibitors.
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Table.32.  ASSOCIATION BETWEEN INHIBITOR DEVELOPMENT
AND RESPONSE TO TREATMENT
Response to
treatment
Inhibitor Positive Inhibitor Negative
p value
.000
Frequency Percentage Frequency Percentage
YES 0 0% 83 100%
NO 3 42.9% 4 57.1%
FIGURE.35.ASSOCIATION BETWEEN INHIBITOR & RESPONSE TO
                                              TREATMENT
In our study, 7 patients showed poor response to Factor VIII treatment, 3
were developed   inhibitors.
This  was statistically significant with  p value of 0.000
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Table.33. ASSOCIATION BETWEEN INHIBITOR DEVELOPMENT &
FRESH FROZEN PLASMA TRANSFUSION
FFP
Transfusion
Inhibitor Positive Inhibitor Negative
p value
0.408
Frequency Percentage Frequency Percentage
YES 3 4.5% 64 95.5%
NO 0 0% 23 100%
FIGURE.36.ASSOCIATION BETWEEN INHIBITOR &FFP
TRANSFUSION
Out of 90 patients, 67 patients had exposure to FFP transfusion, among
them 3 patients had developed inhibitors.
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DISCUSSION.
The development of inhibitors (inhibitory antibodies) against exogenous
FVIII remains a most serious complication  in the management of haemophilia
A .It will make a significant impact on both the morbidity, mortality  and three
times increase the cost of treatment.35 The presence of inhibitors has major
effects on bleeding control, arthropathy status and quality of life .Inhibitors
reduce the efficacy of hemostatic treatment.49 Management of patients who
develop inhibitors is a challenge even in the developed world.71
With this background, the aim of our study is to find out the prevalence
of inhibitors and   analyse the risk factors which are involved  in the
development  of inhibitors.
Several risk factors involved in inhibitor formation including patient
related factors which are severity of haemophilia, genetic mutation, HLA
genotype, race, ethnicity,  and family history of inhibitors. In addition to this,
the therapy related factors like, type of FVIII product  either recombinant or
plasma derived FVIII , age at which first exposure to FVIII therapy, number of
exposures, dose of factor VIII given, duration  between two consecutive 5
exposure days also plays a role in inhibitor.78 Another risk factor is intense
immunologic stimulation (eg. Surgery) during initial exposure days (<50 days)
has the significant correlation with inhibitor development .59
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Out of 90 patients screened, the age range  of patients with haemophilia
A was 3-58 years. All were males. In the  coagulation profile of haemophilia A
patients, mean of APTT was113.5 seconds  (range was 48.20 to 240.80).FVIII
levels were in the range of <1% - 22%.The patients were categorized as mild
,moderate  and severe based on the Factor VIII level.  Out of 90 patients,
59(65.6%) were diagnosed as sever hemophiliacs, moderate and mild were
27(30%) and 4(4.4%) respectively .Our study results shows
severe>moderate>mild. This finding is supported by Wang et al. In his study,
he also reported severe is more common than mild and moderate. his study
results shows severe(77.2%) > moderate (17.4%)> mild (5.4%).72 This findings
are in accordance with the finding of soucie et al, in his study about occurrence
of haemophilia A in US ,he reported  the severe haemophilia A was commoner
than mild and moderate.85
PREVALENCE OF INHIBITORS:
Out of 90 patients 3(3.3%) were positive on inhibitor screening
.Bethesda assay was performed to quantify the inhibitors in these three
haemophilia A patients. Out of 3 two were low titre inhibitor (2.2%) one was
high titre (1.1%). Our study of 90 haemophilia A patients the prevalence of
Factor VIII inhibitor was 3.3%.This findings are similar to the study done by
Wang et al for the prevalence of inhibitors in Chinese Haemophilia A patients
those who were treated only with plasma derived FVIII, fresh frozen plasma or
cryoprecipitate, was 3.9% out of 1435 patients.72 Another study done in UK by
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Wight J et al reported the prevalence of 5-7%.73 The inhibitor prevalence in our
study is similar to the other study done by Ghosh et al in India which is 8.2%
out of 352 patients.63. Another study in India done by  Mathews et al showed
the prevalence was 13% out of 200 patients.71 In a study done by Dubey et al
,the prevalence was 5.1% (n=5)out of 114.52 The data from all the Indian
studies show lower inhibitor prevalence as compared with developed
countries.71 Low prevalence of inhibitors in our patients, may be due to scarce
availability of factor concentrates and delayed initiation of factor replacement
therapy.52  Stonebreaker et al , in his study he found out the prevalence of
inhibitors in high income countries (12.8±6) was higher than lower income
countries(6.6±4.8).Aledort  et al described the possible causes  for under
reporting the cases of hemophilia may be due to lack of diagnostic capability
and scarcity of Factor VIII replacement therapy
Inhibitors are classified according to their levels in plasma as a high titre
inhibitors ,with  the activity ?5 Bethesda units(BU)/ml or a low titre inhibitor
type with the activity of <5 BU/ml.55 In our study only one patient was found to
have high titre  inhibitors and the remaining two had  low titres .
S.No Age (yrs)
APTT(Control
28-36 secs)
FVIII%
INHIBITORTITRE
BU/ml
1. 25 119.80 <1% 1.3
2. 35 180.00 <1% 4.8
3. 37 180.46 <1% 10
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I.PATIENT RELATED RISK FACTORS:
The mean age of patients in the study is 22.95 years. In our study the
age of patients ranged from 3 years to 54 years. The mean age of the patient for
inhibitor development is 32.3 yrs. Ghosh et al reported the mean age at
development of inhibitors was 17.7 years (range 6±52 years).63 In his study, he
found out ,one severe haemophilia A patient was detected inhibitor during his
42 years of age. Mathew et al says while doing the cross sectional study, it was
not possible to assess the age at which inhibitors first developed or comment on
the duration of their persistence.70. Factor VIII inhibitors rise in patients with
haemophilia A throughout life with a bimodal risk.27 As life expectancy
increases, the rising incidence of inhibitor development in older patients with
severe haemophilia A will become a more important clinical challenge.
Kempton et al explains that the older haemophilia A patients have more
exposures compared with younger patients, therefore considered to be at a
higher risk for inhibitor development. Similar finding was observed from
analysis of the United Kingdom Nationwide Database by Hay and colleagues.74
Family History of  Haemophilia  A  :
Out of the total 90 patients, half of the patients {52 (57.8%)}, had
positive family history.  Among the 52, 41 were diagnosed as severe
haemophilia A,(p value 0.004) .Further, all three inhibitor positive patients are
belonged to severe haemophilia A with positive family history. However the
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association between inhibitor development and positive family history is
statistically insignificant with the p value of 0 .132.This finding is supported by
Gouw et al, he reported the inhibitor risk was similar in patients with positive
and negative family history of hemophilia.59
FAMILY H/O INHIBITOR:
Former and recent studies on inhibitor development showed that patients
with severe haemophilia A and positive family  history  of inhibitor are at
highest risk of developing an inhibitor .79,80,81,82 In our study  out of 3 inhibitor
positive patients ,two (40.0%) had positive family history of inhibitors. In our
study the association between family history of inhibitor and the inhibitor
development is statistically significant with the p value (.007). The risk of
developing inhibitors was 3 fold higher in patients with a family history of
inhibitors than in patients with a negative family history .59.Out of inhibitor
positive patients 1/3 had the sibling with the h/o inhibitor. Gill et al reported
that the risk of inhibitor development in the hemophilic sibling of an inhibitor
patient is approximately 50%.
         The second possible cause is genetic. Some hemophiliacs with certain
type of mutation like large deletion, null mutation, inversion 22, of their F8
gene may be more prone to develop inhibitors. Family members often share the
same gene mutation. This explains why development of inhibitors runs in
families. 73
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CONSANGUINITY:
        Out of 90 patients, 16 patients (17.8%) had the positive history for
consanguineous. Out of 3 inhibitor developed patients, one patient (6.3%) had
positive history for consanguineous. The results of two independent studies
showed, 10 fold higher incidence seen in consanguineous marriage.19,76
However this finding is statistically insignificant in our study.
SEVERITY OF HAEMOPHILIA:
All patients who developed inhibitors belonged to severe hemophilia
which is in accordance with finding that severe hemophilia is a risk factor for
inhibitor development.59 Out of 90 patients, 59(65.6%) patients are belonged to
severe hemophilia. Out of 59 patients, 3 (5.1%) were positive for inhibitors.
This finding is similar to a study done by Jenny et al in which 11% of
individuals with severe haemophilia developed inhibitors following plasma
derived factor VIII transfusion. This finding was supported by Wang et al ,in
his study  the prevalence of inhibitor developed more common in
severe(4.3%),then moderate(2.4%)followed by mild(2%).72. However, the
prevalence of inhibitors in patients with severe haemophilia A reported from
developed countries is as high as 30%. Mutation in the F8 gene has a predictive
value in the severity of disease will have the influence of development of
inhibitors. Among patients with severe hemophilia A, large deletion,intron 22
inversion and stop codon association will have 35% risk of inhibitor
formation.19
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II. TREATMENT RELATED RISK FACTORS:
AGE AT WHICH  FIRST  EXPOSURE TO FACTOR VIII :
In our study all inhibitor positive patients receive their first dose of
Factor VIII in the age group between 10 -20 years of age. This is contrast
finding to several studies which showed that most inhibitors develop in
children with severe haemophilia ,exposure to FVIII during the first 6 months
of life.42 According to Lorenzo et al the early exposure (< 6 months) to FVIII
therapy is the risk factor for inhibitor development.87 Other various studies,
CANAL study and Chalmers study, Bom et al showed the relationship between
inhibitor development and treatment characteristics in previously untreated
patients with severe haemophilia A and confirmed that an early age of first
exposure to FVIII was associated with an increased risk of inhibitor
development.42 However further analysis showed that this association was
disappeared after adjustment of dose of FVIII & intensity of exposure.59 In our
study ,the association between inhibitor development and age at first exposure
was statistically insignificant (p value .791).This finding was supported by
Gouw et al, in his study he explained there was no apparent relation between
age at first treatment and risk of developing clinically relevant inhibitors.
NUMBER OF EXPOSURE DAYS:
In CANAL study showed that the highest risk of developing inhibitors
was observed within the first 50 exposures to  FVIII ,with the risk reducing
after 200 treatment days.45 In our study all the inhibitors developed after the 50
exposure days ,but within 150 exposure day. These patients are not followed up
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in a single centre hence the number of exposure days are obtained from the
patient history, which may not be infallible. Considering the fact the patients
had their inhibitors detected after the 50 exposure days. However this finding
was not statistically significant in our study.
 DURATION BETWEEN EXPOSURE DAYS:
Reduced duration between exposure days was significantly associated
with increased risk of inhibitor development.45 In our study, 4 patients had the
history of this intensive treatment, among the 4 patients 3 had developed
inhibitor .this association is statistically significant with the p value of 0.000.
Duration between the 5 consecutive   exposure days was fewer than 10 days,
the relative risk of inhibitor development was 1.9 times higher than the
duration between the exposure days was 10 to 50 days.59 The duration between
the two consecutive exposure days was reduced, it indirectly indicates the
increased frequency of FVIII exposures with the increased risk of inhibitor
formation.59
DOSE OF FACTOR VIII:
 In our study ,all 3 inhibitor positive patients had  been administered the
dose of FVIII is >50IU/Kg body ,this association was statistically significant
with the p value 0.007.this finding was supported by Gouw et al, he reported
that ,the inhibitor development was 3.3 times higher in patient receiving the
mean dose of >50IU/kg.59
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RESPONSE TO TREATMENT:
In our study, all 3 patients positive for inhibitors showed poor response
to therapy. This had a statistically significant p value of 0.000.The similar
finding was observed   by darby et al, in his study he showed the association
between poor response   to treatment and inhibitor development.75
SURGERY  DURING INITIAL 50 EXPOSURE DAYS :
     Among 3 inhibitor developed patients, one had exposure to surgery at
the initial exposure days. Gouw et al reported that the intense stimulation to
immune system (surgeries) or any intense replacement therapy  within 50days
of exposure were associated with an increased risk of developing inhibitors.59
 FFP/CRYOPRECIPITATE  TRANSFUSION :
                  Out of 90 patients, 67 had been treated with both
FFP/cryoprecipitate and plasma derived Factor VIII therapy while remaining
23 patients had exposed only to Factor VIII therapy. All inhibitor developed
patients had exposed to both FFP/cryoprecipitate and plasma derived Factor
VIII. Initial period, because of the scarcity of factor concentrates they had been
treated with FFP and cryoprecipitate, then switch over to plasma derived Factor
VIII concentrates. According to kavakali et al the patients been exposed only to
FFP showed the lower incidence of inhibitor. This statement is supported by
Ghosh et al and oren et al, they have reported the  FFP/cryoprecipitate and
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whole blood have much less potential  to develop inhibitors than highly
purified factor concentrates. Gouw et al and Kempton et al  reported ,
switching among the products was not associated with inhibitor formation.25,36
Out of 67 patients who had exposed to both FFP/cryoprecipitate  and plasma
derived Factor VIII therapy ,one patient was positive for hepatitis B surface
antigen.
         Among the clinical manifestations, our study showed the patients with
severe haemophilia A had the manifestations of umbilical stump bleeding (p
value 0.03), spontaneous bleeding into joints and muscles (0.000) and
hematuria with the p value of 0.050 .The complications of inhibitor
development, the intra cranial haemorrhage  was  observed    in one patient
with the p value of 0.000.
None of our patients   had received prophylactic treatment and recombinant
FVIII products.
COMPARISON OF OUR STUDY WITH OUTCOME OF OTHER STUDIES
PREVALENCE OF INHIBITOR.
             Our study               OTHER STUDIES
Place Prevalence
(No. of patients studied)
Author Place Prevalence(No.of patients  studied)
Chennai  3.3%(90) Wight et al UK 5-7% (1770)
Rasi et al FINLAND 17.3% (110)
Wang et al CHINA 3.9% (1435)
Oren et al TURKEY 5-10% (58)
Owaidah et al SAUDI 29.3% (148)
Ghosh et al Mumbai 8.2% (352)
Dubey et al Lucknow 5.1% (118)
Mathewset al CMC Vellore   12% (200)
II.RISK FACTORS FOR INHIBITOR DEVELOPMENT  :
RISK FACTORS Our
stud
y
Gou
w
et al
Wan
g
et al
Santagostin
o et al
Chambos
t et   al
Chalmer
s et al
Lorenz
o et al
Yee
TT
Kreu
z et al
Ore
n et
al
Malm
o et al
Ghos
h et al
Kavakal
i et al
Severe <1
IU/ml
YES YES YES - - - - YE
S
- YES YES YES YES
Family h/o
hemophilia
YES YES - YES - YES - YE
S
- - - - -
Family h/o
Inhibitors
YES YES YES YES - YES - - YES - YES - -
Age at which first  exposure
FVII
NO YES - YES YES YES YES - YES - - - YES
Doseof
FVIII>50IU/ml/kg
YES YES - YES YES - - - - - - - -
Reduced
Duration between
exposure days
YES YES - YES YES YES - - - - - - -
First50 exposure days NO YES - YES - - - - - - - - YES
Surgerywithinfirst50exposur
e days
NO YES - - YES - - - - - - - -
FFP  less
potential
- - - - - - YES - - YES - YES YES
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SUMMARY
In our study
? 90   patients who had taken treatment for Haemophilia A  were
screened for inhibitor assay.
? The age range of the study group was 3 to 58 years.
? All were males.
? Out of 90 patients screened, 59 were diagnosed as severe
haemophilia A, 27 were moderate haemophilia A, 4 were mild
haemophilia A.
? Out of 59 patients with severe haemophilia 51 were diagnosed
before the age of 1 (p value <0.05)
? The clinical manifestations of bleeding were significant among
severe haemophilia patients. ( p value <0.05)
? Among 59 patients with severe haemophilia 41 had positive family
history. (p value <0.05)
? Out of 90 patients, 23 had been treated only by plasma derived
factor VIII; the remaining 67 had exposure to FFP and
cryoprecipitate in addition to plasma derived factor VIII.
? None of our patients had  received  recombinant  Factor  VIII .
? Mode of treatment for all patients was  on demand  therapy
? 3 out of 90 patients had developed inhibitor against the exogenous
Factor VIII.
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In this study, we observed the following
RISK FACTORS FOR INHIBITOR DEVELOPMENT:
? All 3 patients who had developed inhibitors belonged to severe
haemophilia.
? Among the 3 severe haemophilia patients who had developed
inhibitors, 2 had positive family history of inhibitor development.
(p value <0.05)
? Patients who had administered the Factor VIII   dose of >50IU/kg
have more risk for inhibitor development. Our  study shows
significant association  with the p value of <0.05
? The patients had undergone more intense treatment that is interval
between five consecutive exposure  days were less than 10 days have
more risk for inhibitor development. Our study shows significant
association with p value of  <0.05.
? Patients who did not show clinical response in spite of adequate
Factor VIII therapy are at more risk for inhibitor development. Our
study shows significant association between poor response to
treatment and inhibitor development ( p value  < 0.05).
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CONCLUSION
In our study, we observed a significant correlation between the
development of inhibitors and modifiable treatment related risk factors such as
intense treatment and dose of Factor VIII. The non-modifiable patient related
risk factors correlating with inhibitor development were seen in severe
haemophilia A patients and with positive family history of development of
inhibitors.
The genetically prone patients should be screened regularly for early
recognition for the development of Factor VIII inhibitors. In these patients, if
the modifiable treatment related risk factors are avoided, Factor VIII
refractoriness due to inhibitor development can be delayed.
Further, once the patient had developed inhibitors to Factor VIII
concentrates, the cost of care rises exponentially. Hence, it is imperative to
adhere to the standard treatment guidelines and delay the development of
inhibitors by diligent identification of avoidable risk factors.
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PATIENT INFORMATION SHEET
       Inhibitor development in Haemophilia A patients greatly complicates the
therapy .Patients with inhibitors experience bleeding that is harder to control once it
starts. This study is done to assess the prevalence of inhibitor in haemophilia patients ,
will help the physician to change the mode of treatment and prevent the complications
of inhibitors development
PROCEDURE  :
  Data will be collected from   Patients   and  Case  records
BENEFITS AND  RISKS  :
If patients developed inhibitors against factor VIII must be informed to the
physician, and the mode of treatment will be changed. Minimal risk for patients
enrolled in this study.
CONFIDENTIALITY  :
     Your privacy will be protected in so for as permitted by law. Only your
researcher and Ethical committee members will have access to the data collected
during the study.
PARTICIPATION :
       Your participation in this study is voluntary and you are free to decide now or
later whether to continue or discontinue from the study.
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????? ??? ??????? ???, ?? ? ???? ???? ??????
?????? 8 ?? ??? ?? ??? ?? ???? ? ???? ??? ? ????? ?
???.
??? ????
????? ??? ??????? ???, ?? ? ???? ???? ?????
??????? ??? , ???????? ?????? 8 ?? ??? ?? ??? ?? ????
?????? ??????????? ????.
??????
??????? ?? ???????? ??? ????? ????
??????? ?? ?? ?? ?? ???? ???????. ?? ? ??????
????? ???????? ????? ??.??. ? ?????
??????????? ?? ???????????? ?????
??????????.
?????????? ????
????? ??? ??????? ??? ?????? ??? ?? ???? ?
??????? ???????????????.??????? ??????? ?
???? ? ??? ????? ???? ????? ????????
????? ?????.????? ??????? ? ?? ? ?? ??? ????????
.????????????? ??? ? ?? ? ???? ?????? ????????
????? ???????
???????????? ?? ????? ????? ?? ????
??????????? .????? ??????? ??? ??? ???
??????? ? ?????? ???? ?????? ????????????????
????
????? ?
??? ??????? ? ????? ????? ? ??????????.???
??????? ? ????? ????? ?? ??
??????????,?? ??????? ??? ???????????
??????? .
??????? ? ????
????????
????
CONSENT
I confirm that I read and understood the information about the above research
study dated ______________ and I received chance to ask the questions.
My participation in this study is voluntary and I know that I am free to
withdraw from the study at any time, without giving any reason and without
affecting of my legal rights.
I agree to this access. I know that my identification will not be revealed in any
details that is released to third persons or published.
I agree not to restrict or interfere with any data or results that are obtained
from this study. I agree to participate in this research study for the above listed
purpose.
Patient’s name                     :
Signature                              :                                                             Date    :
Patient IP Number               :
Signature of the person
who obtains consent            :                                                              Date    :
??????????
?????? ????? __________________________________ ????
?????? ??? ??? ? ??????? ??? ???? ??? ? ????
???????,?? ?????? ???? ?? ?? ??. ?? ??? ?
????? ? ????????? ???? ????? ??? ????????? ????
????? ??.
??? ???? ?? ??????? ???? ? ?? ?? ??? ??????
?????????? ? ???????.??? ????????? ?? ??? ???
??? ???? ???? ????????? ??? ???? ? ?? ???????
????????? ?? ?? ????? ???? ??????? ???????
??? ????????
?????????? ????? ??? ??????? ????? ??
??? ?????? ?? ??. ??? ??????????,??????
????????? ???? ?? ?????? ??? ???? ? ????
??????,??? ??????? ???? ??? ???
????? ??????????????????????? ????????.
??? ???? ??? ??????? ?????????? ????
??????? ?????????? ????????? ??? ?????? ???
???? ??? ?? ?? .?????? ??? ????? ???? ?????
?????? ????????? ???? ?????? ??? ???????
???? ????????? ?? ??
??????? ????
???????? ????
???????????????????? ????
                                                PROFORMA
Name of the patient       :                                            In  Patient Number :
Age /Sex                        :                                            Blood group            :
Diagnosis                       :                                            Age of Diagnosis    :
Clinical manifestations :
Hemarthrosis                  :  Yes/No                            Most common joint affected:
Haematomas                  :   Yes/No                            Muscle involvement :
Spontaneous bleeding    :   Yes/No
Frequency of bleeding episodes /year :
Gum bleeding :
 Epistaxis       :
Retroperitoneal bleed :
Hematuria  :
Umbilical stump  bleed :
Intracranial haemorrhage :
Crippling arthropathy :
Family h/o haemophilia  : Yes/No
Family h/o inhibitor         : Yes/No
H/o consanguinity            :Yes/No
H/o surgery                      :
Whether Mother had bleeding manifestations :
Siblings have the history of  haemophilia :
Treatment History ;
  Factor VIII  Infusion :
                   Age at  first exposure  :
             Number of infusions
             Regular prophylaxis/on demand:
             Response to therapy:
             Date of last infusion :
             Dose of Factor VIII concentrate/infusion :
             Interval between the two infusions :
Details of other  blood component Transfusion
                           FFP ,Cryoprecipitate, :
                           Number of Transfusions
